By SIRION Biotech…
To get in touch with SIRION Biotech GmbH, simply fill out the form below.
Subscribe to Supplier
SIRION brings viral vector expertise to BioFIT 2020 virtual event
Martinsried, Germany: – Europe’s leading supplier of viral vector technologies, SIRION Biotech, will bring its leading edge insights and opportunities to the BioFIT 2020 partnering conference for the life sciences industry, being hosted from Lille in France as an all-digital event.
This will be SIRION’s debut appearance at BioFIT, where it will use the sophisticated one-to-one networking platform and virtual exhibition to reach out to new partners and collaborators.
LV, AV and AAV development
SIRION is ready to discuss new opportunities to harness its world-leading expertise and proprietary technologies in lentivirus (LV), adenovirus (AV), and adeno-associated virus (AAV) vector development for Gene & Cell therapies.
“We have two main motivations to attend BIOFIT 2020: to support the French and European drug discovery ecosystem by bringing our technologies and knowledge to potential partners, and to identify new technologies that require our development expertise to bring them faster to market,” explained SIRION Senior Director Francois Vromman, who heads Business Operations for Southern and Western Europe.
Creating new value
“We welcome all opportunities to discuss ways in which our broad expertise and understanding of viral vector technologies for different applications can help create new unique value propositions,” said Mr Vromman.
SIRION will be active in seeking out online meetings with business developers, Academic Tech transfer teams, and biotech and pharma innovators evolving new gene and cell-based therapies.
“Our natural partners are those seeking technological innovation, open collaborations, matching technologies, and advanced services and expertise in viral vector technologies,” said Mr Vromman, who will be available for online meetings throughout the four day event.
About SIRION Biotech
Founded at Martinsried, near Munich, in 2007, SIRION Biotech has become Europe’s leading commercial supplier of viral vectors used for genetic research, clinical target validation, cell and gene therapy, and vaccination studies. It is SIRION’s mission to change the paradigm for viral vector supplies, with their ability to develop and supply all major viral vector types (adenovirus, lentivirus, AAV) within a matter of weeks at the concentration titres and quantities needed for preclinical human and animal testing.
Its unique focus on improving transduction efficiencies and safety makes SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST™ transduction reagent is actively used to improve, for example, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies. SIRION offerings include the RNAiONE™ knockdown validation platform for short-hairpin RNA (shRNA) screening along with a full range of virus related services, ranging from viral particle production to virus driven cell modelling.
SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry.
Learn more at: www.sirion-biotech.com
About BioFIT Digital 2020
BioFIt has become one of Europe’s leading partnering events for technology transfer and academia-industry collaborations in the field of Life Sciences, offering a 360° approach to sourcing early-stage innovations.
With a highest attendee rate among academics, TTOs and research institutions, BioFIT is the starting place for many academia-industry connecxtions, acting as a platform to build partnerships for all public and private actors.
Now in its ninth year, BioFit 2020 will be hosted from Lille in France as a four day event oopening December 7, adopting an all-digital vrtual format to meet the challenges of the COVID-19 pandemic and incorporatng the sister MedFIT partnering paltform for the /Medtech, Diagnostic and Digital Health sectors.
The combined online events will feature 24 hours a day pre-qualified one-to-one meetings via the Inova partnering system, live and recorded conferences and roundtable discussions (available for 30 days afterwards, along with presentations from start-ups and notifications of collaborative and licensing opportunities. BioFIT also includes an animal health track and a virtual exhibition.
The event is organized by Eurasanté with more information at: http://www.biofit-event.com
Click on SIRION Biotech Viral Vectors to learn more about custom adenovirus, lentivirus and adeno-associated viral vector services.